Background: Low high-density lipoprotein cholesterol (HDL-C) is an important clinical risk factor for cardiovascular disease (CVD).
Introduction
Serum high-density lipoprotein cholesterol (HDL-C) is known to be a protective marker for cardiovascular disease (CVD). In the Framingham study, lower HDL-C levels were indicated as a higher risk of Some clinical trials have reported that statins increased HDL-C levels by 5 − 15% [5] [6] [7] [8] ; however, the long-term effects of statins on HDL-C have not been studied well in Japanese patients.
Pitavastatin (LIVALO Tablet 1 mg or 2 mg) is an HMG-CoA reductase inhibitor, which was reported to reduce low-density cholesterol (LDL-C) and triglyceride (TG) by enhancing LDL receptors and suppressing the secretion of very low-density lipoprotein (VLDL) 9) in animal models. Clinical studies conducted prior to its approval in Japan revealed that pitavastatin has efficacy in not only lowering LDL-C, but also lowering TG and raising HDL-C 10) . The LIVALO effectiveness and safety (LIVES) study was a large-scale, long-term, prospective postmarketing surveillance of pitavastatin, including more than 20,000 hypercholesterolemia patients under ordinary clinical practice 11) . Using the database of the LIVES study, we analyzed the effects of pitavastatin on HDL-C as well as on LDL-C and TG in patients who were followed, by the end of the study. The clinical factors that might affect HDL-C elevation were also analyzed.
Subjects and Methods

Survey Participants
The design and results of the LIVES study were described previously 11) . Patients with hypercholesterolemia or familial hypercholesterolemia were registered in this study. Patients were enrolled using a central registration system, with each patient enrolled in the study within 14 days after the start of treatment with pitavastatin. Patients were observed during 2 years after the start of treatment until dropout. Of the 20,279 patients recruited, 19,925 patients were analyzed for safety and 18,031 patients were analyzed for the effectiveness of pitavastatin.
In this study, the data of 18,031 patients were analyzed for effectiveness. Since the main objective of the LIVES study was to recognize any unknown adverse reactions and evaluate the incidence and pattern of adverse reactions, not all efficacy data were always available during the whole study period. Thus, from these patients, lipid changes were analyzed in patients whose efficacy data were eligible at 104 weeks.
Lipid Analysis
Percent change of TC, LDL-C, TG (all and high TG group ( 150 mg/dL) at baseline), HDL-C (all and low HDL-C group ( 40 mg/dL) at baseline), non-HDL-C, and LDL-C/HDL-C were calculated. Concentration of LDL-C was estimated using the Friedewald formula (LDL-C TC HDL-C TG 0.2) 12) for patients with TG concentration 400 mg/dL.
Time course of LDL-C, TG (high TG group), and HDL-C (all patients and low HDL-C group) for 104 weeks was evaluated in patients whose efficacy data were all available at 0, 12, 28, 52, and 104 weeks. The increasing trend of HDL-C was analyzed by the linear regression model.
Percent change of HDL-C in patients pre-treated other statins and other cholesterol lowering drugs was also evaluated.
Analysis of Clinical Factors Affecting HDL-C
The effect of clinical factors, patient baseline characters (gender, pre-or post-menopausal, age, BMI, phenotype of dyslipidemia, and smoking), complication (hypertension, diabetes, heart disease, liver disease, and renal disease), other pre-treated cholesterollowering drug, and dose of pitavastatin, on the change of HDL-C was evaluated.
Statistical Analysis
All data are expressed as the mean standard deviation. Statistical analysis was performed with a one-sample t test or paired t test in appropriate data. Time course of LDL-C, TG and HDL-C was analyzed by one-way ANOVA for the study period. In factorial analysis, the percent change of HDL-C was adjusted by the baseline HDL-C and analyzed by the ANOVA (F-test). Multivariable analysis was applied by the stepwise method to select factors affecting percent change of HDL-C. JMP ver. 5.1.1 was used for statistical analysis with a significant level of p 0.05 (twosided).
Results
Effects on Plasma Lipids Levels
Of the total 18,031 patients, 4,086 were used to evaluate TC, 1,455 LDL-C, 4,123 TG, and 3,427 HDL-C, respectively, as patients whose data were available at 104 weeks. The number of patients with baseline TG levels of 150 mg/dL or over was 2,088 (50.6%), and baseline HDL-C levels of less than 40 mg/dL was 346 (10.1%). The demographic characteristics of patients in the LIVES study and this sub-analysis are shown in Table 1 . The data in this sub-analysis were similar to those of all patients in the LIVES study. Both the average initial daily dose and most frequent daily dose of LIVALO were 1.62 mg/day.
Percent changes of serum lipids at 104 weeks are listed in Table 2 . A significant reduction of TC ( 21.0%) and LDL-C ( 31.3%) was observed at 104 weeks. Also, non-HDL-C and LDL-C/HDL-C were reduced significantly (p 0.0001) at 104 weeks. The percent reduction of TG was 6.1% for the entire population but was 24.2% in the high TG group. The percent increase of HDL-C was 5.9% (p 0.0001) for the entire population and 24.6% (p 0.0001) in the low HDL-C group.
The time course of LDL-C, TG (the high TG group), and HDL-C (all patients and the low HDL-C group) for 104 weeks is shown (Fig. 1, 2, 3) . Significant reduction of LDL-C was observed at 12 weeks ( 32.9%). The reduction rate of LDL-C was stable and was 36.1% at 104 weeks (p 0.001; ANOVA). The reduction rate of TG was 21.7% at 12 weeks and a greater reduction rate ( 28.3%) was observed at 104 weeks (p 0.001; ANOVA). In the analysis of all patients, HDL-C was elevated by 2.3% at 12 weeks, and by 7.5% at 104 weeks (p 0.05; ANOVA).
In the analysis of low HDL-C level patients, HDL-C was elevated by 14.0% at 12 weeks, and by 24. Values are the mean HDL-C than pre-treated patients in both all patients and the low HDL-C group (p 0.01). In the group of pre-treated patients, the percent change of HDL-C was compared among the pretreated drugs. A further increase of HDL-C was observed after switching from other statins.
Analysis of Clinical Factors Affecting HDL-C
Clinical factors influencing the percent change of HDL-C were investigated (Table 3 ). In the ANOVA (F-test), gender, menopausal, BMI, diabetes, liver disease, and pre-treated other cholesterol-lowering drug were detected as significant factors affecting the change of HDL-C.
Factors selected by the step-wise method were followed by multivariable analysis. BMI, diabetes, liver disease, and pre-treated other cholesterol-lowering drugs were confirmed as significant factors affecting HDL-C elevation (Table 4) .
Safety
Of the 19,925 patients included in the safety evaluation, 2,069 (10.4%) developed adverse drug reactions. The major adverse drug reactions were blood creatine phosphokinase increased (2.74%), alanine aminotransferase (ALT) increased (1.79%), aspartate aminotransferase (AST) increased (1.50%), myalgia (1.08%) and gamma-glutamyltransferase increased (1.00%). Most of the adverse drug reactions were mild (mild in 1,735 patients, moderate in 307 patients and serious in 27 patients).
Discussion
In the current study, pitavastatin showed favorable effects on LDL-C, TG, and HDL-C for 104 
Adjusted HDL-C baseline Adjusted HDL-C baseline weeks in hypercholesterolemic patients. In particular, it is noted that HDL-C was increased significantly in both all patients and the low HDL-C group after 104 weeks, indicating that pitavastatin is effective for elevation of HDL-C. Barter et al. analyzed Treating to New Targets (TNT) Study data and reported that patients with lower HDL-C levels have a significant higher risk of CAD than patients with higher HDL-C levels even though their LDL-C is controlled under 70 mg/dL 13) . Also, in the BIP trial, it is suggested that HDL-C level-raising therapy is associated with longterm mortality reduction 14) . Thus, it is suggested that pitavastatin may be beneficial to prevent CVD and reduce mortality due to elevating HDL-C in addition to lowering LDL-C.
The lipid values shown in Table 2 were from patients whose data were available at both 0 and 104 weeks, and the time course data were from patients whose data were available all 0, 12, 28, 52 and 104 weeks. Percent changes of LDL-C, TG, and HDL-C were almost the same in Table 2 and the time-course data.
As for analysis of the lipid profile for 104 weeks, it was shown that pitavastatin increased HDL-C continuously until 104 weeks. This increasing trend of HDL-C was also observed in a long-term treatment study of pitavastatin conducted before its launch in clinical use 15) . In the J-LIT study, an increasing trend was observed by simvastatin for long-term treatment 4) . On the other hand, in long-term treatment studies of other statins, increasing trends of HDL-C were not observed 16) ; therefore, increasing effects on HDL-C might be different among statins in long-term treatment.
In this study, pitavastatin showed a significant effect to increase HDL-C even after switching from other cholesterol-lowering drugs. Consistently, Sasaki et al. reported that pitavastatin elevated HDL-C significantly more than atorvastatin 17) . The potential mechanisms of raising HDL-C by pitavastatin have been reported. Maejima et al. reported that pitavastatin induced apoA-I more efficiently than simvastatin and atorvastatin, and increased ABCA1 mRNA in a dose-dependent manner in HepG2 cells 18) . Saiki et al. added that pitavastatin increases the activity of LPL, which metabolizes VLDL and elevates HDL-C, compared with other stains 19) . It is currently unknown whether these mechanisms are common in statins or are subclass effects that highlight HDL-C elevation by pitavastatin over other statins.
Diabetes was indicated as a significant clinical factor affecting HDL-C elevation. It is well known that diabetes patients have lower levels of HDL-C and a higher risk of CVD than non-diabetes patients 20) . Recently, it was reported that adiponectin influences the value of HDL-C 21) . Pitavastatin increases adiponection in hyperlipidemic patients 22) . Since the concentration of adiponectin is lower in diabetes patients than non-diabetes patients 23) , adiponectin could mediate HDL-C elevation in diabeteic patients by pitavastatin.
In this study, we analyzed the efficacy of pitavastatin under actual use conditions using the database of the LIVES study. Since the main purpose of the LIVES study is to generate safety information, in some patients the efficacy data were not available. Therefore, a further prospective long-term clinical trial is needed to evaluate the HDL-C increasing trend of pitavastatin. Also, additional research is required to reveal the mechanisms of HDL-C elevation and its difference between statins.
In conclusion, pitavastain showed potent beneficial effects on LDL-C, TG, and especially HDL-C for 104 weeks, suggesting that pitavastatin may decrease the risk of CVD by maintaining a favorable HDL-C level.
